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Abstract
Colorectal cancer (CRC) is one of the cancer models 
and most of the carcinogenic steps are presently well 
understood. Therefore, successful preventive measures 
are currently used in medical practice. However, CRC is 
still an important public health problem as it is the third 
most common cancer and the fourth most frequent 
cause of cancer death worldwide. Nowadays, pathologic 
stage is a unique and well-recognized prognostic indica-
tor, however, more accurate indicators of the biologic 
behavior of CRC are expected to improve the specificity 
of medical treatment.  Angiogenesis plays an important 
role in the growth and progression of cancer but its role 
as a prognostic factor is still controversial. Probably the 
most important clinical implication of tumor angiogen-
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esis is the development of anti-angiogenic therapy.  The 
goal of this review is to critically evaluate the role of 
angiogenic markers, assessed by either endoglin-related 
microvessel density or expression of vascular endothelial 
growth factor family members in the CRC setting and 
discuss the role of these angiogenic markers in anti-
angiogenic therapies. 
© 2011 Baishideng. All rights reserved.
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COLORECTAL CANCER EPIDEMIOLOGY
Colorectal cancer (CRC) is the third most common cancer 
and the fourth most frequent cause of  cancer death world-
wide[1-3]. Globally, CRC incidence varies widely, with higher 
rates in North America, Australia and Western Europe and 
lower rates in developing countries [4], although, in recent 
years, high CRC rates have also been reported in these 
countries[5]. In terms of  mortality, geographic disparities 
have also been observed[6]. In Western countries, CRC is 
sults were reported by Abdalla et al and Choti et al, with 
a 5-year overall survival rate of  58% following resec-
tion[21] and a rate of  67% described by de Haas et al[22].. 
These higher survival rates likely reflect improvements 
in patient selection, perioperative and postoperative care, 
multidisciplinary treatment, and an appropriately ag-
gressive approach to safe hepatic resection[21]. Therefore, 
early diagnosis is critical to improve survival rates in 
CRC[23] and owing to its typically slow growth, there is a 
large potential for reducing the burden of  the disease by 
early detection and removal of  precancerous lesions or 
early cancer stages[24].
On the other hand, the pathologic clinical stage is 
currently the single most well-established prognostic 
indicator, but it does not fully predict individual clinical 
outcome[7, 25, 26]; also, the response of  clinically-identical tu-
mors to the same treatment may be vastly different[1]. This 
is particularly contentious for those tumors with interme-
diate stage disease (Stage Ⅱ, T3-T4N0M0)[7], where one 
third of  patients with tumor-free lymph nodes have recur-
rences, and therefore, adjuvant chemotherapy may be ben-
eficial[27]. In this group, carcinoma cells are not detected 
in lymph nodes by conventional staging methods in 24% 
of  patients. Surgical technique and specific pathological 
staining may improve staging accuracy and the appropriate 
selection of  patients for chemotherapy[27]. Furthermore, 
the identification of  cancer penetration or perforation is 
particularly important in defining CRC aggressiveness[14]. 
Accordingly, identification of  prognostic molecular mark-
ers capable of  categorizing those patients at high-risk, 
would be very helpful for improving treatment strategies 
mainly in lymph node negative patients, determining the 
characteristics of  patients’ outcome, predicting cancer dis-
semination and recognizing which patients might benefit 
most from adjuvant chemotherapy and those unlikely to 
benefit thus sparing them the toxicities of  treatment[14, 
27-29]. 
Molecular markers may improve clinicopathologic 
staging and provide a basis to guide novel therapeutic 
strategies which target specific tumor-associated molecules 
according to individual tumor biology[1, 2, 7, 14], however, so 
far, no ideal molecular marker has been found to predict 
disease progression[29]. 
HIGHLIGHTS OF THE ANGIOGENESIS 
PHENOMENON
Angiogenesis plays a key role in tumorigenesis and meta-
static processes[1, 28, 30]. It consists of  the formation of  new 
blood vessels from the endothelium of  pre-existing vas-
culature[2, 30]. Sprouting from existing blood vessels is the 
principal process of  angiogenesis and involves prolifera-
tion of  activated endothelial cells, migration of  endothelial 
cells to reach remote targets, assembly of  endothelial cells 
into new capillary tubes, followed by synthesis of  a new 
basement membrane and maturation of  vessels with for-
mation of  a vascular lumen[30]. However, recruitment and 
in situ differentiation of  bone marrow-derived endothelial 
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the second most common cause of  death from malignant 
disease, and despite improvements in treatment mortality 
remains high with metastatic spread to the liver occurring 
in about 50% of  patients[7]. 
European countries rank highest in the global statis-
tics, both in terms of  CRC incidence and mortality. From 
1998 to 2002, the incidence of  CRC in Europe for men 
and women was 38.5 and 24.6 (world age standardization 
(ASR-W)) per 100 000 inhabitants and mortality over the 
same period was 18.5 and 10.7 (ASR-W) per 100 000 in-
habitants, respectively[8]. However, over the past twenty-
five years, mortality rates among Caucasians have steadily 
declined[9]. Data from the World Health Organization 
(WHO), between 1997 and 2007 have revealed that mor-
tality from CRC declined by around 2% per year from 
19.7 to 17.4/100 000 for men (world standardized rates), 
and from 12.5 to 10.5/100 000 for women, and these re-
cent decreases in CRC mortality rates in several European 
countries are likely due to improvement in earlier diagno-
sis and treatment, with a consequent higher survival[10]. 
CRC incidence is generally higher in men, and the 
risk increases with age, as the majority of  cases are diag-
nosed in patients older than 50 years[1, 3, 8], with only 5% 
of  cases recorded in patients younger than 40 years[1]. 
A large nationwide study identified CRC as one of  the 
10 most commonly diagnosed cancers among men and 
women aged 20-49 years[11].  The prevalence of  advanced 
CRC also increases with age and is higher among men 
than women[12]. 
COLORECTAL CANCER PROGNOSIS AND 
DISEASE PROGRESSION
The main prognostic factors in CRC are tumor size (T), 
lymph node involvement (N), grade of  differentiation (G) 
and distant disease spread (M)[1-3,9,13,14]. Other important 
factors include invasion of  blood and/or lymphatic ves-
sels and penetration or perforation of  the bowel wall[14]. 
Long-term survival correlates with stage of  the dis-
ease[9, 15-17], and this is the most important predictor of  
mortality. The five-year survival rate for localized disease 
is 90.4%, but only 39% of  CRC is diagnosed at this 
early stage[9, 16]. Approximately 15-20% of  patients die 
as a consequence of  CRC in early stages compared with 
40-80% in advanced stages[15]. The overall 5-year survival 
rate varies among studies but is approximately 60%[9, 15, 
16]. Stage-specific survival rates are 96%, 87%, 55%, and 
5% for TNM stage Ⅰ, Ⅱ, Ⅲ, and Ⅳ, respectively[9,17,18]. 
One third of  the patients submitted to curative intent 
surgery die of  local and/or distant tumoral recurrence 
[15]. Among the sites of  metastasis, liver is the organ 
most frequently involved (38%-60% of  cases), followed 
by abdominal lymph nodes (38%), lung (38%) and peri-
toneum (28%)[14]. Of  those diagnosed with metastatic 
disease, less than 10% are still alive after 5 years[16]. The 
5-year overall survival rates for patients in whom hepatic 
resection was technically feasible and who had metastasis 
confined to the liver was only 25%-40%[7,19,20]. Better re-
progenitor cells are also involved[30]. 
Tumor angiogenesis is essential to allow neoplastic 
mass development favoring access to the blood com-
ponents, and also strengthening the vascular routes in the 
metastatic process[25, 31-33]. Neovascularization as a whole 
promotes tumor growth by supplying nutrients, oxygen 
and releasing growth factors that promote tumor cell 
proliferation[25, 30, 34-36]. Hypoxia in solid tumors occurs at a 
distance of  ≥ 70 μm from functional blood vessels and it 
is generally accepted that tumors do not exceed a volume 
of  1-2 mm3 without induction of  angiogenesis[36]. Intra-
tumoral vasculature density is believed to be associated 
directly with cancer cell entrance into the systemic blood 
circulation, with the ability of  cancer cells to invade locally 
normal anatomic structures, and the establishment of  
blood-borne metastases in distant organs[32, 37]. Regulation 
of  tumor angiogenesis is the result of  a complex balance 
between many stimulatory and inhibitory factors, which 
are secreted by both tumor cells and host-infiltrating cells 
as well as by tumoral stroma-cells activity[2, 30, 34]. Malignant 
neoplastic cells promote angiogenesis by secreting growth 
factors such as vascular endothelial growth factor (VEGF), 
hepatocyte growth factor (HGF) and platelet-derived 
growth factor (PDGF), among others that stimulate endo-
thelial migration and proliferation[2,25,31,33,37,38]. 
The role of  angiogenesis as a prognostic factor, how-
ever, is still controversial[13, 39]. Weidner et al first reported a 
direct correlation between the incidence of  metastasis and 
the number and density of  blood vessels in invasive breast 
cancers. Similar studies have endorsed this correlation in 
gastrointestinal cancers[33] and in a variety of  malignancies[2, 
7, 13, 25, 35, 37]. An association between increased angiogenesis 
and an increased incidence of  metastases and a subsequent 
decrease in survival curve rates was observed for the vast 
majority of  solid tumors[2, 7, 3, 25, 35, 37]. 
Several studies revealed high angiogenic activity in 
CRC, which was more likely correlated with aggressive 
histopathological features that included parietal invasion, 
tumor stage, grade of  tumor differentiation, metastatic 
potential and poor patient survival[1, 13, 32]. Tanigawa[35] et al 
confirmed this premise, although a significant variation in 
patient populations and techniques was used, which can 
explain, in part, the inverse relationship between tumor 
vascularity and patient survival observed by these authors. 
Gurzu[13] et al added that augmented angiogenesis in CRC 
was higher in early-stages of  tumoral proliferation but was 
not a progressively increasing process, having rather an 
oscillating character. 
However, other studies revealed that angiogenesis 
does not provide any significant information[13, 28, 30]. 
These controversial statements may be credited to the 
lack of  standardization of  the different methods of  
counting tumoral blood vessels and to the different cut-
offs used to define relevant parameters to consolidate 
the results and, lastly, to the different antibodies used to 
highlight the blood vasculature[13, 28, 30]. 
Despite the debates, assessment of  tumor angiogen-
esis may be particularly useful in prognostic classification 
of  patients with apparent early cancer by conventional tu-
mor staging, some of  which may still develop early recur-
rence or metastasis (despite being staged as having early 
cancers by conventional parameters such as tumor size)[30]. 
De Vita[37] et al  observed that highly angiogenic tumors 
were associated with the presence of  lymph node invasion 
. Nevertheless, a higher percentage of  patients with node-
positive colon cancer than those without will experience 
recurrence and might benefit from anti-angiogenic adju-
vant therapy. Thus, angiogenesis can be used to identify a 
subset of  patients at high risk for recurrence regardless of  
their lymph node involvement[35]. 
There is evidence that blood vessel density is also im-
portant in predicting cancer response to chemotherapy or 
radiotherapy[20]. Angiogenic tumors have a more aggressive 
phenotype and the degree of  intra-tumoral microvessels is 
significantly predictive of  poor response to platinum-based 
chemotherapy in terms of  complete response, as seen in 
two studies, one in squamous cell carcinoma patients[40] and 
the other in patients with epithelial ovarian cancers[41]. In 
addition, Takagi[42] et al observed that blood vessel density 
was a valid predictor of  the effects of  intra-arterial targeted 
carboplatin chemotherapy and concurrent radiotherapy 
for treating human oral and oropharyngeal squamous cell 
carcinomas. Zhang[43] et al, trying to identify reliable predic-
tive factors for local control of  hypopharyngeal cancer 
(HPC) treated by radiotherapy, observed that microvessel 
density (MVD) in biopsy specimens was closely correlated 
with local control of  HPC treated by radiotherapy. In one 
study of  28 patients with advanced gastric cancer treated 
by paclitaxel and carboplatin, tumors with medium MVD 
showed a significantly higher response rate compared with 
those with either a high or low MVD[44]. Long course of  
radiotherapy significantly decreased angiogenesis in rectal 
cancer tissue. MVD have been found to be a favorable 
marker for tumor behavior during radiotherapy and a pre-
dictor of  overall survival after a long course of  radiothera-
py. Further investigations are now needed to determine the 
changes in angiogenesis during a shorter course of  radio-
therapy[1]. However, the most important clinical implication 
of  tumor angiogenesis is probably the development of  
anti-angiogenic therapy, targeting tumor vessels instead of  
cancer cells[30]. 
ENDOGLIN AND ASSESSMENT OF MI-
CROVESSEL DENSITY AS ANGIOGENIC 
MARKERS
Microvessel density (MVD) assessment is the most com-
mon technique used to quantify intratumoral and peritu-
moral angiogenesis in cancer[2, 7, 28, 30, 39]. It was first devel-
oped by Weidner et al in 1991 who used pan-endothelial 
immunohistochemical staining of  blood microvessels, 
mainly with Factor VIII related antigen (F. VIII Ag or 
von Willebrand’s factor), CD31 or CD34, and rarely 
CD105[2]. 
Measurement of  angiogenesis is complicated by the 
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fact that it is a dynamic process. Intra-tumoral micro-
vessels can be identified by immunostaining of  endothelial 
cells by two categories of  human endothelial cell-specific 
antibodies: the pan-endothelial cell markers and specific 
antibodies that bind selectively to proliferating endotheli-
um[44, 45]. CD31 is utilized as the pan-endothelial marker of  
choice; it is characterized by equal intensity of  staining for 
small and large vessels. The disadvantages associated with 
staining for CD31 antigen include co-staining of  inflam-
matory cells. The selective antibodies, such as endoglin, 
distinguish quantitatively between tumor neovasculariza-
tion and pre-existing vessels with no or poor staining of  
lymphatics and normal quiescent blood vessels[46]. Most 
studies revealed that high MVD predicts occurrence of  
metastatic disease[2, 7, 13, 25, 32, 35, 37], and although tumor an-
giogenesis is unlikely to be the only factor responsible, it 
provides large numbers of  leaking blood vessels for vas-
cular invasion[25]. 
Endoglin (CD105) is a receptor for the TGF-β1 mol-
ecule that is up-regulated in tumor angiogenesis [13, 25, 29]. 
Its secretion is induced by hypoxia[29] and, as it is present 
mainly in new vessels, it is very useful in the assessment 
of  newly formed vessels in malignant neoplasms[13, 25, 29]. 
It is also currently accepted as a potential target for anti-
angiogenic therapy, especially in cancer patients at risk of  
developing metastases[29]. The endoglin antibody binds 
preferentially to the activated endothelial cells that partici-
pate in tumor angiogenesis, however, endoglin expression 
is weak/or negative in vascular endothelium of  normal 
tissues; accordingly, it is a more specific and sensitive 
marker of  tumor angiogenesis than the others commonly 
used such as pan-endothelial markers[25, 29]. Intra-tumoral 
MVD determined by immunohistochemical staining for 
endoglin has been reported to be an indicator of  poor 
prognosis in many types of  solid neoplasia such as breast 
carcinoma, cervical cancer, endometrial carcinoma, gastric 
carcinoma, melanoma, some testicular tumors, non-small 
cell lung cancer, prostate cancer, renal cell carcinoma and 
squamous cell carcinoma[29]. 
In CRC, many reports indicate that endoglin assessed 
immunohistochemically correlates not only with MVD, 
but also with survival curves, and it has also been identi-
fied as a valuable parameter for predicting increased risk 
of  developing metastatic disease[25, 29,42]. Yan[47] et al report-
ed that MVD was higher in CRC patients with metastases 
than in those without and observed that the specificity 
and sensitivity of  MVD in predicting metastatization in 
CRC was 66.22% and 51.72%, respectively. In other stud-
ies, the presence of  endoglin also had a prognostic mean-
ing, showing a positive correlation with the presence of  
angio-lymphatic invasion, lymph node metastases, tumor 
stage and hepatic metastases, reinforcing the premise that 
endoglin might be considered for further therapeutic trials 
as anti-angiogenic therapy[25, 29]. 
Endoglin is not only expressed on the cell surface 
but its soluble form can also be detected in the blood[29, 
48]. Myśliwiec[29]et al demonstrated an apparent continu-
ous endoglin rise in plasma from patients with metastatic 
colorectal cancer, and Li[48] et al reported that circulating 
endoglin levels positively correlated with CRC Dukes’ 
stage and survival; patients with a high MVD, above the 
median 3.10 × 250, showed the worst prognosis. Taka-
hashi[49] et al observed that increased serum endoglin was 
associated with metastasis in patients with solid tumors 
including colorectal and breast carcinomas; and, in CRC 
patients, the difference in endoglin levels between the 
metastasis-negative patients and the metastasis-positive 
patients was statistically significant. Conversely, it was 
recently demonstrated that assessment of  endoglin in 
plasma is not a useful maker of  CRC, but might be help-
ful in selecting patients with metastatic diseas[29]. 
VASCULAR ENDOTHELIAL GROWTH 
FACTOR FAMILY AND CRC  
Quantification of  angiogenic factors in solid malignant 
tumors provides an alternative to MVD evaluation in as-
sessing tumor angiogenic activity[28, 30]. Numerous studies 
have demonstrated that tumor overexpression of  vas-
cular endothelial growth factor (VEGF) correlates with 
high tumor MVD and is associated with advanced tumor 
stage or tumor invasiveness in various common human 
cancers[30, 37, 50, 51] and, its overexpression in colon cancer 
tissue indicates poor prognosis[51]; although paradoxically, 
some data showed that MVD might have a significant 
prognostic value in colon cancer tissue, whilst VEGF 
has not[52]. 
VEGF is the most widely studied angiogenic factor; 
it increases vascular permeability and is the most potent, 
direct acting, angiogenic protein known[28, 29, 36, 37, 52]. Nor-
mally, VEGF is weakly expressed in a wide variety of  hu-
man and animal tissues;  however, high levels of  VEGF 
expression can be detected at sites where physiologic 
angiogenesis is required, such as fetal tissue or placenta, or 
in the vast majority of  human tumors and other diseases 
i.e., chronic inflammatory disorders, diabetes mellitus, and 
ischemic heart disease[37]. Furthermore, both VEGF and 
its receptors are expressed at high levels in metastatic hu-
man colon carcinomas and in tumor-associated endotheli-
al cells, respectively[37]. Consequently, VEGF is recognized 
as a prominent angiogenic factor in colon carcinoma and 
the assessment of  VEGF expression may be useful for 
predicting metastasis from CRC[37]. In fact, VEGF expres-
sion was found to be higher in patients with metastatic 
tumors than in those with non-metastatic tumors[37,38], 
and high levels of  VEGF expression were associated with 
advanced cancer stage and related with unfavorable prog-
nosis[51-53].  
De Vita et al [37] reported that preoperative serum 
VEGF levels might be useful for predicting the outcome 
of  colon cancer patients following surgery. After surgery, 
VEGF levels tend to decrease compared with preopera-
tive concentrations[30, 37]. Conversely, elevated VEGF levels 
after surgery may indicate significant residual disease, even 
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if  it is not evident macroscopically[37]. 
Other studies have shown that VEGF is also a use-
ful marker for prognosis by significantly correlating with 
angio-lymphatic invasion, lymph node status and depth 
of  invasion, notwithstanding it was not an independent 
prognostic factor[25, 29]. 
Although numerous publications dealing with the 
measurement of  circulating VEGF for diagnostic and 
therapeutic monitoring have been published, the relation-
ship between the production of  tissue VEGF and its con-
centration in blood is still unclear[31]. Some of  the contro-
versies regarding the clinical value of  VEGF serum level 
measurement are related to the well-known fact that cir-
culating VEGF is largely found in platelets, and as a con-
sequence an open debate is ongoing to clarify if  VEGF 
serum levels truly reflect tumor expression of  VEGF 
or whether there are other potential sources of  circulat-
ing VEGF, such as blood cells[30]. Cressey[31] et al  noted 
that the cell-associated isoform (VEGF189), but not the 
soluble isoforms (VEGF121 and VEGF165) appear to 
play an important role in tumor progression. In addition, 
Serum VEGF protein levels are a prognostic parameter 
for progression-free and overall survival in CRC. Patients 
with high soluble VEGF levels might have a more aggres-
sive disease, and the improved outcome observed in their 
series might be a reflection of  the disease biology[54,55]. 
The effect of  VEGF depends not only on tumor 
cell expression of  VEGF, but also on the VEGF recep-
tors in the endothelial cells[30]. The ligands of  the VEGF 
family include VEGF-A, VEGF-B, VEGF-C, VEGF-D 
and VEGF-E; and the receptors are VEGFR-1, R-2 and 
R-3[56]. 
VEGF-A is commonly overexpressed by a wide variety 
of  human tumors, and this overexpression has been corre-
lated with progression, invasion and metastasis, MVD, and 
poorer survival and prognosis[56]. In CRC, VEGF-A is the 
ligand of  the VEGF family most abundantly expressed[29]. 
VEGF-A promotes angiogenesis through enhancement of  
permeability, activation, survival, migration, invasion, and 
proliferation of  endothelial cells[57]. VEGF-A and VEGF-B 
play a role in early tumor development at the stage of  ad-
enoma formation[7, 58]. 
Myśliwiec[29] et al found a strong positive association 
with VEGF-A plasma concentrations assessed post-
operatively and the presence of  distant metastases. Zlo-
bec[59] et al also correlated high VEGF expression with re-
sponse to preoperative radiotherapy in patients with rectal 
tumors. 
VEGF-C and -D are glycoproteins structurally similar 
and sharing areas of  sequence homology with VEGF-A. 
In CRC, augmented VEGF-C expression has been found 
to correlate with lymphatic invasion and lymph node 
metastasis[60]. Elevated levels of  serum VEGF-C have 
been found in patients with breast cancer, lung cancer 
and cervical cancer and it appears to be an independent 
marker for early diagnosis of  cancer metastasis. Moreover, 
increased VEGF-C mRNA expression in tumor tissues 
correlates positively with lymphatic metastasis and poor 
prognosis[61]. A correlation between VEGF-D expression 
levels in the primary tumor and lymph node metastasis is 
still disputable, with controversial data reported[62]. 
Another important fact is that through the deve-
lopment of  anti-angiogenic therapy, CRC prognosis is 
improving[30, 63-65]. Median survival of  patients with meta-
static CRC (mCRC) treated with best supportive care is 
approximately 6 mo. Palliative chemotherapy considerably 
improves treatment outcome, with fluorouracil (FU) plus 
irinotecan and/or oxaliplatin extending median overall 
survival to approximately 20 mo[66]. Thus, in the past de-
cade, the median overall survival of  patients with mCRC 
has increased from 12 mo to approximately 20 mo, mainly 
due to the development of  new combinations with stan-
dard chemotherapy[67]. Currently, anti-angiogenic treat-
ment can prolong the survival time by some months, how-
ever, the results are not reproducible for all cases[13]. There 
have been clinical trials which show as many as 94% of  
invasive carcinomas and 88% of  in situ carcinomas having 
a complete response[68]. Unfortunately, there are no tumor 
characteristics or molecular markers at present that help 
to identify patients who are likely to benefit from anti-
angiogenic treatment[69]. 
 Bevacizumab (BV) is a monoclonal antibody against 
VEGF with anti-angiogenic properties, and several clini-
cal trials supported the use of  BV in the first-line treat-
ment of  mCRC[70]. BV is typically used in combination 
with other chemotherapeutic agents such as oxaliplatin, 
irinotecan, leucovorin, and 5-fluorouracil (5-FU) for treat-
ment of  patients with mCRC[70, 71]. In addition to its direct 
anti-angiogenic effects, BV may also improve the delivery 
of  chemotherapy by changing tumor vasculature and 
decreasing the elevated interstitial pressure in tumors[69]. 
When combined with standard chemotherapy regimens, 
it has been associated with significant improvements, 
compared with chemotherapy alone, in the efficacy end 
points of  overall survival, progression-free survival, and 
response rates in patients with mCRC, and for some fa-
cilitates secondary resections[72]. Jubb[73] et al demonstrated 
that in patients with mCRC, the addition of  BV to irinote-
can, 5-FU/leucovorin (IFL) improves survival regardless 
of  the level of  VEGF expression, or MVD. In a review 
by Tappenden[74]et al, the addition of  BV to IFL resulted 
in a statistically significant increase in median overall sur-
vival (OS) of  4.7 mo, and in a median progression-free 
survival (PFS) of  4.4 mo. An overall tumor response rate 
of  44.8% was reported for BV plus IFL compared with 
34.8% for IFL plus placebo within one study. In a pivotal, 
placebo-controlled, phase III trial in patients with mCRC 
(Genentech Study 2107), the addition of  BV to IFL re-
sulted in a significantly longer survival time (20.3 vs 15.6 
mo) and progression-free survival time (10.6 vs 6.2 mo) 
than with IFL plus placebo[73, 75-78]. In a placebo-controlled, 
phase II trial (Genentech Study 2192), adding BV to 5-FU 
plus LV resulted in a significantly longer progression-
free survival time than with 5-FU and LV plus placebo in 
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patients with mCRC who were unsuitable candidates for 
first-line therapy with irinotecan (9.2 vs 5.5 mo). There 
was also a trend towards a longer survival time in patients 
receiving 5-FU, LV, and BV (16.6 vs 12.9 mo)[77]. BV was 
also tested in mCRC combined with an oxaliplatin-based 
regimen in the second-line setting. In this randomized 
phase Ⅲ trial (E3200), patients with previously treated 
CRC were randomized into 3 arms: FOLFOX4 plus BV, 
FOLFOX4 and BV only. Results showed superior sur-
vival and progression-free survival in the FOLFOX4 plus 
BV arm. In this study, BV was equally effective with the 
oxaliplatin-based regimen[78]. 
BV ultimately achieved FDA approval in 2004 as a 
first-line treatment for mCRC in combination with che-
motherapy, based on its statistically and clinically meaning-
ful benefits on progression-free survival and OS and has 
since garnered additional approval[79]. BV is the most used 
VEGF inhibitor with clear proof  of  efficacy in CRC, how-
ever, optimal use of  this agent at various stages of  the dis-
ease is still under investigation. Additionally, there are nu-
merous other angiogenic agents targeting VEGF and other 
pro-angiogenic systems in clinical development[80]. These 
novel targeted agents inhibit the VEGF pathway by target-
ing the VEGF ligand, its receptors or by blocking down-
stream signaling pathway components. Anti-angiogenic 
agents include antibodies, small molecule tyrosine kinase 
(TK) inhibitors, antisense oligonucleotides and aptamers[81]. 
Table 1 summarized the main results of  CD105 and 
VEGF studies.
CONCLUSION 
Despite major advances, in terms of  knowledge and 
treatment of  CRC in recent years, the single most well-
documented prognostic marker of  pathologic stage 
remains the gold standard for disease stage at diagnosis. 
Angiogenesis plays an important role in the growth and 
progression of  cancer but its role as a prognostic factor 
is still controversial. Most studies report that endoglin 
and vascular endothelial growth factor family expres-
sion are indicators of  poor prognosis in CRC patients. 
Beyond these controversies, the ultimate clinical implica-
tion of  tumor angiogenesis is the development of  anti-
angiogenic therapy, targeting tumor vasculature. 
REFERENCES
1 Svagzdys S, Le�sauskaite� V, Pavalkis D, Ne�dze�lskie�ne� I, 
Pranys D, Tame�lis A. Microve�sse�l de�nsity as ne�w prognos�
tic marke�r afte�r radiothe�rapy in re�ctal cance�r. BMC Cancer 
2009�� 9�� 95
2 Des Guetz G, Uzzan B, Nicolas P, Cuche�rat M, More�re� JF, 
Be�namouzig R, Bre�au JL, Pe�rre�t GY. Microve�sse�l de�nsity 
and VEGF e�xpre�ssion are� prognostic factors in colore�ctal 
cance�r. Me�ta�analysis of the� lite�rature�. Br J Cancer 200��� 94�� 
1�23�1�32
3 Brenner H, Hoffme�iste�r M, Haug U. Should colore�ctal can�
ce�r scre�e�ning start at the� same� age� in Europe�an countrie�s? 
Contributions from de�scriptive� e�pide�miology. Br J Cancer 
200��� 99�� 532�535
4 Aljebreen AM. Clinico�pathological patte�rns of colore�ctal 
cance�r in Saudi Arabia�� younge�r with an advance�d stage� 
pre�se�ntation. Saudi J Gastroenterol 200��� 13�� �4���
5 Center MM, Je�mal A, Smith RA, Ward E. Worldwide� varia�
tions in colore�ctal cance�r. CA Cance�r J Clin 2009�� 59�� 3���3��
� Henry KA, Niu X, Boscoe� FP. Ge�ographic disparitie�s in 
colore�ctal cance�r survival. Int J Health Geogr 2009�� 8�� 4�
� Barozzi C, Ravaioli M, D'Errico A, Grazi GL, Poggioli G, 
Cavrini G, Mazziotti A, Grigioni WF. Re�le�vance� of biologic 
marke�rs in colore�ctal carcinoma�� a comparative� study of a 
broad pane�l. Cancer 2002�� 94�� �4���5�
� Zavoral M, Suchane�k S, Zavada F, Duse�k L, Muzik J, Se�ife�rt 
B, Fric P. Colore�ctal cance�r scre�e�ning in Europe�. World J Gas-
troenterol 2009�� 15�� 590��5915
9 Alexander DD, Wate�rbor J, Hughe�s T, Funkhouse�r E, 
Grizzle� W, Manne� U. African�Ame�rican and Caucasian dis�
paritie�s in colore�ctal cance�r mortality and survival by data 
source��� an e�pide�miologic re�vie�w. Cancer Biomark 200��� 3�� 
301�313
10 Bosetti C, Le�vi F, Rosato V, Be�rtuccio P, Lucchini F, Ne�gri E, 
La Ve�cchia C. Re�ce�nt tre�nds in colore�ctal cance�r mortality in 
Europe�. Int J Cancer 2011�� 129�� 1�0�191
2�� June� 10, 2011|Volume� 2|Issue� �|WJCO|www.wjgne�t.com
  Study n High levels of CD105 
were associated with
High levels of VEGF 
were associated with
  Barozzi et al[�] 101 M1 M1
  Saad et al[25] 150 M1, N1 and angiolymphatic invasion                  N1, angiolymphatic and de�pth of invasion
  De� Vita et al [3�]    �1 NE                      NCs �se�rum le�ve�ls�
  Cascinu et al[3�] 121 NE RR
  Myśliwiec et al[29]  4� M1                    Colore�ctal cance�r patie�nts �plasma le�ve�ls�
  Li  et al[4�]  111 Duke�s' stage�s and survival NE
  Takahashi et al[49]   34 M1 NE
  Liang et al[51] 114 NE                  N1, TNM staging and  poor prognosis
  Zhe�ng et al[52]    9� NE                  Poorly diffe�re�ntiate�d ade�nocarcinoma
  Cre�sse�y et al [31]   �� NE TNM
  Cao et al[53]   �1 NE N1, M1, TNM, and OS
  Miyazaki et al[5�] 12� NE RR, DF, OS �plasma le�ve�ls�
Table 1  The main results of CD105 and VEGF studies
DF�� Dise�ase��fre�e��� M1�� Positive� distant me�tastasis�� N1�� Positive� lymph node� me�tastasis�� NCs�� Non�curative� surge�ry�� NE�� Not e�valuate�d�� OS�� Ove�rall survival�� 
RR�� Re�curre�nce� rate�
11 Fairley TL, Cardine�z CJ, Martin J, Alle�y L, Frie�dman C, Ed�
wards B, Jamison P. Colore�ctal cance�r in U.S. adults younge�r 
than 50 ye�ars of age�, 199��2001. Cancer 200��� 107�� 1153�11�1
12 Brenner H, Alte�nhofe�n L, Hoffme�iste�r M. Se�x, age�, and 
birth cohort e�ffe�cts in colore�ctal ne�oplasms�� a cohort analy�
sis. Ann Intern Med 2010�� 152�� �9���03 
13 Gurzu S, Jung J, Azamfirei L, Mezei T, Cîmpean AM, Szen�
tirmay Z. The� angioge�ne�sis in colore�ctal carcinomas with 
and without lymph node� me�tastase�s. Rom J Morphol Embryol 
200��� 49�� 149�152
14 Cascinu S, Ge�orgoulias V, Ke�rr D, Maughan T, Labianca R, 
Ychou M. Colore�ctal cance�r in the� adjuvant se�tting�� pe�rspe�c�
tive�s on tre�atme�nt and the� role� of prognostic factors. Ann 
Oncol 2003�� 14 Suppl 2�� ii25�ii29
15 Calvo HJ, Orte�ga GD,  Pardo RJM,  Lópe�z, MAJ, Cubo T. 
Biologia mole�cular de�l proce�sso me�tastásico de�l cance�r colo�
re�ctal. Cirugia Española 2000, 68 �� 5���5��        
1� Zafar SY, Abe�rne�thy AP, Abbott DH, Grambow SC, Mar�
ce�llo JE, He�rndon JE 2nd, Rowe� KL, Kolimaga JT, Zullig LL, 
Patwardhan MB, Prove�nzale� DT. Comorbidity, age�, race� and 
stage� at diagnosis in colore�ctal cance�r�� a re�trospe�ctive�, paral�
le�l analysis of two he�alth syste�ms. BMC Cancer 200��� 8�� 345
1� Ries LA, Wingo PA, Mille�r DS, Howe� HL, We�ir HK, Rose�n�
be�rg HM, Ve�rnon SW, Cronin K, Edwards BK. The� annual 
re�port to the� nation on the� status of cance�r, 19�3�199�, 
with a spe�cial se�ction on colore�ctal cance�r. Cancer 2000�� 88�� 
239��2424
1� Townsend MC, Be�auchamp D, Eve�rs MB, Mattox LK. Sabis�
ton Te�xtbook of Surge�ry, 1�th e�d.�� Saunde�rs�� Canada, 200�
19 Liu CL, Fan ST, Lo CM, Law WL, Ng IO, Wong J. He�patic 
re�se�ction for colore�ctal live�r me�tastase�s�� prospe�ctive� study. 
Hong Kong Med J 2002�� 8�� 329�333  
20 Lambert LA, Colacchio TA, Barth RJ. Inte�rval he�patic re�se�c�
tion of colore�ctal me�tastase�s improve�s patie�nt se�le�ction* 
Curr Surg 2000�� 57�� 504
21 Abdalla EK, Vauthe�y JN, Ellis LM, Ellis V, Pollock R, 
Broglio KR, He�ss K, Curle�y SA. Re�curre�nce� and outcome�s 
following he�patic re�se�ction, radiofre�que�ncy ablation, and 
combine�d re�se�ction/ablation for colore�ctal live�r me�tastase�s. 
Ann Surg 2004�� 239�� �1��25�� discussion �25��2�     
22 de Haas RJ, Wiche�rts DA, Flore�s E, Azoulay D, Castaing D, 
Adam R. R1 re�se�ction by ne�ce�ssity for colore�ctal live�r me�tas�
tase�s�� is it still a contraindication to surge�ry? Ann Surg 200��� 
248�� �2���3� 
23 Lang K, Korn JR, Le�e� DW, Line�s LM, Earle� CC, Me�nzin J. 
Factors associate�d with improve�d survival among olde�r 
colore�ctal cance�r patie�nts in the� US�� a population�base�d 
analysis. BMC Cancer 2009�� 9�� 22�
24 Brenner H, Hoffme�iste�r M, Arndt V, Haug U. Ge�nde�r dif�
fe�re�nce�s in colore�ctal cance�r�� implications for age� at initia�
tion of scre�e�ning. Br J Cancer 200��� 96�� �2���31
25 Saad RS, Liu YL, Nathan G, Ce�le�bre�zze� J, Me�dich D, Silve�r�
man JF. Endoglin �CD105� and vascular e�ndothe�lial growth 
factor as prognostic marke�rs in colore�ctal cance�r. Mod Pathol 
2004�� 17�� 19��203
2� Gómez-Domínguez E, Trape�ro�Marugán M, de�l Pozo AJ, 
Cante�ro J, Gisbe�rt JP, Maté J. The� colore�ctal carcinoma prog�
nosis factors. Significance of diagnosis delay. Rev Esp Enferm 
Dig 200��� 98�� 322�329
2� Bilchik AJ, DiNome� M, Saha S, Turne�r RR, Wie�se� D, Mc�
Carte�r M, Hoon DS, Morton DL. Prospe�ctive� multice�nte�r tri�
al of staging ade�quacy in colon cance�r�� pre�liminary re�sults. 
Arch Surg 200��� 141�� 52��33�� discussion 533�534.
2� Graziano F, Cascinu S. Prognostic mole�cular marke�rs for 
planning adjuvant che�mothe�rapy trials in Duke�s' B colore�c�
tal cance�r patie�nts�� how much e�vide�nce� is e�nough? Ann On-
col 2003�� 14�� 102��103� 
29 Myśliwiec P, Pawlak K, Kukliński A, Kedra B. Combined 
pe�riope�rative� plasma e�ndoglin and VEGF��a asse�ssme�nt in 
colore�ctal cance�r patie�nts. Folia Histochem Cytobiol 2009�� 47�� 
231�23�       
30 Pang RW, Poon RT. Clinical implications of angioge�ne�sis in 
cance�rs. Vasc Health Risk Manag 200��� 2�� 9��10� 
31 Cressey R, Wattananupong O, Le�rtprase�rtsuke� N, Vinit�
ke�tkumnue�n U. Alte�ration of prote�in e�xpre�ssion patte�rn of 
vascular e�ndothe�lial growth factor �VEGF� from soluble� to 
ce�ll�associate�d isoform during tumourige�ne�sis. BMC Cancer 
2005�� 5�� 12�
32 Giatromanolaki A, Stathopoulos GP, Tsiompanou E, 
Papadimitriou C, Ge�orgoulias V, Gatte�r KC, Harris AL, 
Koukourakis MI. Combine�d role� of tumor angioge�ne�sis, 
bcl�2, and p53 e�xpre�ssion in the� prognosis of patie�nts with 
colore�ctal carcinoma. Cancer 1999�� 86�� 1421�1430
33 Kitadai Y. Angioge�ne�sis and lymphangioge�ne�sis of gastric 
cance�r. J Oncol 2010�� 2010�� 4���25
34 Kwon KA, Kim SH, Oh SY, Le�e� S, Han JY, Kim KH, Goh 
RY, Choi HJ, Park KJ, Roh MS, Kim HJ, Kwon HC, Le�e� JH. 
Clinical significance of preoperative serum vascular endo�
the�lial growth factor, inte�rle�ukin��, and C�re�active� prote�in 
le�ve�l in colore�ctal cance�r. BMC Cancer 2010�� 10�� 203 
35 Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, 
Matsuyama K, Muraoka R. Tumor angioge�ne�sis and mode� 
of me�tastasis in patie�nts with colore�ctal cance�r. Cancer Res 
199��� 57�� 1043�104�
3� Mosch B, Re�isse�nwe�be�r B, Ne�ube�r C, Pie�tzsch J. Eph re�ce�p�
tors and e�phrin ligands�� important playe�rs in angioge�ne�sis 
and tumor angioge�ne�sis. J Oncol 2010�� 2010�� 1352�5
3� De Vita F, Orditura M, Lie�to E, Infusino S, Morgillo F, Mar�
tine�lli E, Caste�llano P, Romano C, Ciardie�llo F, Catalano G, 
Pignate�lli C, Galizia G. Ele�vate�d pe�riope�rative� se�rum vas�
cular e�ndothe�lial growth factor le�ve�ls in patie�nts with colon 
carcinoma. Cancer 2004�� 100�� 2�0�2��
3� Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano 
V, Ghise�lli R, Rossi C, Balde�lli AM, Graziano F, Saba V, Mu�
re�tto P, Catalano G. Expre�ssion of vascular e�ndothe�lial gro�
wth factor can pre�dict e�ve�nt�fre�e� survival in stage� II colon 
cance�r. Clin Cancer Res 2000�� 6�� 2�03�2�0� 
39 Rodrigo JP, Cabanillas R, Chiara MD, García Pe�dre�ro J, 
Astudillo A, Suárez Nieto C. [Prognostic significance of an�
gioge�ne�sis in surgically tre�ate�d supraglottic squamous ce�ll 
carcinomas of the� larynx]. Acta Otorrinolaringol Esp 2009�� 60�� 
2�2�2��
40 Gasparini G, Be�vilacqua P, Bonoldi E, Te�stolin A, Galassi A, 
Ve�rde�rio P, Boracchi P, Guglie�lmi RB, Pe�zze�lla F. Pre�dictive� 
and prognostic marke�rs in a se�rie�s of patie�nts with he�ad 
and ne�ck squamous ce�ll invasive� carcinoma tre�ate�d with 
concurre�nt che�moradiation the�rapy. Clin Cancer Res 1995�� 
11��13�5�13�3
41 Hollingsworth HC, Kohn EC, Ste�inbe�rg SM, Rothe�nbe�rg 
ML, Me�rino MJ. Tumor angioge�ne�sis in advance�d stage� 
ovarian carcinoma. Am J Pathol 1995�� 147�� 33�41
42 Takagi S, Ine�naga R, Oya R, Nakamura S, Ike�mura K. Blood 
ve�sse�l de�nsity corre�late�s with the� e�ffe�cts of targe�te�d intra�
arte�rial carboplatin infusion with concurre�nt radiothe�rapy 
for squamous ce�ll carcinomas of the� oral cavity and oropha�
rynx. Br J Cancer 200��� 94�� 15�0�15�5
43 Zhang SC, Miyamoto S, Kamijo T, Hayashi R, Hase�be� T, 
Ishii G, Fukayama M, Ochiai A. Intratumor microve�sse�l 
de�nsity in biopsy spe�cime�ns pre�dicts local re�sponse� of hy�
popharynge�al cance�r to radiothe�rapy. Jpn J Clin Oncol 2003�� 
33�� �13��19
44 Hasan J, Bye�rs R, Jayson GC. Intra�tumoural microve�s�
se�l de�nsity in human solid tumours. Br J Cancer 2002�� 86�� 
15���15��
45 Poon RT, Fan ST, Wong J. Clinical significance of angiogen�
e�sis in gastrointe�stinal cance�rs�� a targe�t for nove�l prognostic 
and the�rape�utic approache�s. Ann Surg 2003�� 238�� 9�2�
4� Romani AA, Borghe�tti AF, De�l Rio P, Siane�si M, Soliani P. 
2�� June� 10, 2011|Volume� 2|Issue� �|WJCO|www.wjgne�t.com
The� risk of de�ve�loping me�tastatic dise�ase� in colore�ctal can�
ce�r is re�late�d to CD105�positive� ve�sse�l count. J Surg Oncol 
200��� 93�� 44��455
4� Yan G, Zhou XY, Cai SJ, Zhang GH, Pe�ng JJ, Du X. Lym�
phangioge�nic and angioge�nic microve�sse�l de�nsity in human 
primary sporadic colore�ctal carcinoma. World J Gastroenterol 
200��� 14�� 101�10�
4� Li C, Gardy R, Se�on BK, Duff SE, Abdalla S, Re�ne�han A, 
O'Dwye�r ST, Haboubi N, Kumar S. Both high intratumoral 
microve�sse�l de�nsity de�te�rmine�d using CD105 antibody and 
e�le�vate�d plasma le�ve�ls of CD105 in colore�ctal cance�r patie�nts 
corre�late� with poor prognosis. Br J Cancer 2003�� 88�� 1424�1431
49 Takahashi N, Kawanishi�Tabata R, Haba A, Tabata M, Ha�
ruta Y, Tsai H, Se�on BK. Association of se�rum e�ndoglin with 
me�tastasis in patie�nts with colore�ctal, bre�ast, and othe�r solid 
tumors, and suppre�ssive� e�ffe�ct of che�mothe�rapy on the� se��
rum e�ndoglin. Clin Cancer Res 2001�� 7�� 524�532
50 Lee SJ, Kim JG, Sohn SK, Chae� YS, Moon JH, Kim SN, Bae� 
HI, Chung HY, Yu W. No association of vascular e�ndothe��
lial growth factor�A �VEGF�A� and VEGF�C e�xpre�ssion with 
survival in patie�nts with gastric cance�r. Cancer Res Treat 
2009�� 41�� 21��223
51 Liang JF, Wang HK, Xiao H, Li N, Che�ng CX, Zhao YZ, Ma 
YB, Gao JZ, Bai RB, Zhe�ng HX. Re�lationship and prognostic 
significance� of SPARC and VEGF prote�in e�xpre�ssion in 
colon cance�r. J Exp Clin Cancer Res 2010�� 29�� �1
52 Zheng S, Han MY, Xiao ZX, Pe�ng JP, Dong Q. Clinical 
significance of vascular endothelial growth factor expression 
and ne�ovascularization in colore�ctal carcinoma. World J 
Gastroenterol 2003�� 9�� 122��1230
53 Cao D , Hou M, Guan YS, Jiang M, Yang Y, Gou HF. 
Expre�ssion of HIF�1alpha and VEGF in colore�ctal cance�r�� 
association with cl inical outcome�s and prognostic 
implications. BMC Cancer 2009�� 9�� 432        
54 Paule B, Bastie�n L, De�slande�s E, Cusse�not O, Podgorniak 
MP, Allory Y, Naïmi B, Porche�r R, de� La Taille� A, Me�nashi S, 
Calvo F, Mourah S. Soluble� isoforms of vascular e�ndothe�lial 
growth factor are� pre�dictors of re�sponse� to sunitinib in 
me�tastatic re�nal ce�ll carcinomas. PLoS One 2010�� 5�� e�10�15
55 Cook KM, Figg WD. Angioge�ne�sis inhibitors�� curre�nt 
strate�gie�s and future� prospe�cts. CA Cancer J Clin 2010�� 60�� 
222�243
5� Duhoux FP, Machie�ls JP. Antivascular the�rapy for e�pithe�lial 
ovarian cance�r. J Oncol 2010�� 2010�� 3�254� 
5� Hanrahan V, Currie� MJ, Gunningham SP, Morrin HR, 
Scott PA, Robinson BA, Fox SB. The� angioge�nic switch for 
vascular e�ndothe�lial growth factor �VEGF��A, VEGF�B, 
VEGF�C, and VEGF�D in the� ade�noma�carcinoma se�que�nce� 
during colore�ctal cance�r progre�ssion. J Pathol 2003�� 200�� 
1�3�194
5� Miyazaki T, Okada N, Ishibashi K, Ogata K, Ohsawa T, 
Ishiguro T, Nakada H, Yokoyama M, Matsuki M, Kato H, 
Kuwano H, Ishida H. Clinical significance of plasma level 
of vascular e�ndothe�lial growth factor�C in patie�nts with 
colore�ctal cance�r. Jpn J Clin Oncol 200��� 38�� �39��43
59 Zlobec I, Ste�e�le� R, Nigam N, Compton CC.A pre�dictive� 
mode�l of re�ctal tumor re�sponse� to pre�ope�rative� radiothe�r�
apy using classification and regression tree methods. Clin 
Cancer Res 2005�� 15 �� 5440�5443
�0 He M, Che�ng Y, Li W, Liu Q, Liu J, Huang J, Fu X. Vascular 
e�ndothe�lial growth factor C promote�s ce�rvical cance�r 
me�tastasis via up�re�gulation and activation of RhoA/
ROCK�2/moe�sin cascade�. BMC Cancer 2010�� 10�� 1�0
�1 Thiele W, Sle�e�man JP. Tumor�induce�d lymphangioge�ne�sis�� 
a targe�t for cance�r the�rapy? J Biotechnol 200��� 124�� 224�241
�2 Stintzing S, He�ine�mann V, Moosmann N, Hidde�mann W, 
Jung A, Kirchne�r T. The� tre�atme�nt of colore�ctal carcinoma 
with monoclonal antibodie�s�� the� importance� of KRAS 
mutation analysis and EGFR status. Dtsch Arztebl Int 2009�� 
106�� 202�20�
�3 Gille J. Antiangioge�nic cance�r the�rapie�s ge�t the�ir act 
toge�the�r�� curre�nt de�ve�lopme�nts and future� prospe�cts 
of growth factor� and growth factor re�ce�ptor�targe�te�d 
approache�s. Exp Dermatol 200��� 15�� 1�5�1�� 
�4 Sparano JA, Gray R, Giantonio B, O'Dwye�r P, Comis RL. 
Evaluating antiangioge�ne�sis age�nts in the� clinic�� the� Easte�rn 
Coope�rative� Oncology Group Portfolio of Clinical Trials. 
Clin Cancer Res 2004�� 10�� 120��1211
�5 Gruenberger B, Tamandl D, Schue�lle�r J, Sche�ithaue�r 
W, Zie�linski C, He�rbst F, Grue�nbe�rge�r T. Be�vacizumab, 
cape�citabine�, and oxaliplatin as ne�oadjuvant the�rapy for 
patie�nts with pote�ntially curable� me�tastatic colore�ctal 
cance�r. J Clin Oncol 200��� 26�� 1�30�1�35
�� Ma AT, Ma BB, Le�i KI, Mo FK, Chan AT. Clinical pre�dic�
tors of re�sponse� to ce�tuximab�che�mothe�rapy in me�tastatic 
colore�ctal cance�r. Hong Kong Med J 2010�� 16�� 20��212 
�� Nussenbaum F, He�rman IM. Tumor angioge�ne�sis�� insights 
and innovations. J Oncol 2010�� 2010�� 132�41
�� Boehm S, Rothe�rmundt C, He�ss D, Joe�rge�r M. Antiangio�
ge�nic drugs in oncology�� a focus on drug safe�ty and the� 
e�lde�rly � a mini�re�vie�w. Gerontology 2010�� 56�� 303�309
�9 Mahfud M , Bre�ite�nste�in S, El�Badry AM, Puhan M, 
Ricke�nbache�r A, Samaras P, Pe�ssaux P, Lope�z�Be�n S, Jae�ck 
D, Figue�ras J, Alain�Clavie�n P. Impact of pre�ope�rative� 
be�vacizumab on complications afte�r re�se�ction of colore�ctal 
live�r me�tastase�s�� case��matche�d control study. World J Surg 
2010�� 34�� 92�100
�0 Tol J, Punt CJ. Monoclonal antibodie�s in the� tre�atme�nt of 
me�tastatic colore�ctal cance�r�� a re�vie�w. Clin Ther 2010�� 32�� 
43��453
�1 Shih T, Lindle�y C. Be�vacizumab�� an angioge�ne�sis inhibitor 
for the� tre�atme�nt of solid malignancie�s. Clin Ther 200��� 28�� 
1��9�1�02
�2 Rougier P, Mitry E. [Targe�te�d biothe�rapy�� a re�volution 
in the� manage�me�nt of patie�nts with colore�ctal cance�r?]. 
Gastroenterol Clin Biol 2009�� 33�� ��2���0
�3 Jubb AM, Hurwitz HI, Bai W, Holmgre�n EB, Tobin P, 
Gue�rre�ro AS, Kabbinavar F, Holde�n SN, Novotny WF, 
Frantz GD, Hillan KJ, Koe�ppe�n H. Impact of vascular 
e�ndothe�lial growth factor�A e�xpre�ssion, thrombospondin�2 
e�xpre�ssion, and microve�sse�l de�nsity on the� tre�atme�nt e�ffe�ct 
of be�vacizumab in me�tastatic colore�ctal cance�r. J Clin Oncol 
200��� 24�� 21��22�
�4 Tappenden P, Jone�s R, Paisle�y S, Carroll C. Syste�matic re�vie�w 
and e�conomic e�valuation of be�vacizumab and ce�tuximab for 
the� tre�atme�nt of me�tastatic colore�ctal cance�r. Health Technol 
Assess 200��� 11�� 1�12�, iii�iv
�5 Naschberger E, Crone�r RS, Me�rke�l S, Dimmle�r A, Tripal 
P, Amann KU, Kre�mme�r E, Brue�ckl WM, Papadopoulos 
T, Hohe�nadl C, Hohe�nbe�rge�r W, Stürzl M. Angiostatic 
immune� re�action in colore�ctal carcinoma�� Impact on 
survival and pe�rspe�ctive�s for antiangioge�nic the�rapy. Int J 
Cancer 200��� 123�� 2120�2129
�� Hurwitz H, Fe�hre�nbache�r L, Novotny W, Cartwright 
T, Hainsworth J, He�im W, Be�rlin J, Baron A, Griffing 
S, Holmgre�n E, Fe�rrara N, Fyfe� G, Roge�rs B, Ross R, 
Kabbinavar F. Be�vacizumab plus irinote�can, fluorouracil, 
and le�ucovorin for me�tastatic colore�ctal cance�r. N Engl J Med 
2004�� 350�� 2335�2342
�� Kabbinavar FF, Wallace� JF, Holmgre�n E, Yi J, Ce�lla D, Yost 
KJ, Hurwitz HI. He�alth�re�late�d quality of life� impact of 
bevacizumab when combined with irinotecan, 5-fluorouracil, 
and le�ucovorin or 5�fluorouracil and le�ucovorin for 
me�tastatic colore�ctal cance�r. Oncologist 200��� 13�� 1021�1029
�� Ma WW, Hidalgo M. Exploiting nove�l mole�cular targe�ts 
in gastrointe�stinal cance�rs. World J Gastroenterol 200��� 13�� 
5�45�5�5� 
�9 Yancopoulos GD. Clinical application of the�rapie�s targe�ting 
2�9 June� 10, 2011|Volume� 2|Issue� �|WJCO|www.wjgne�t.com
VEGF. Cell 2010�� 143�� 13�1�        
�0 Hubbard J, Grothe�y A. Antiangioge�ne�sis age�nts in colore�c�
tal cance�r. Curr Opin Oncol 2010�� 22�� 3�4�3�0 
�1 Prat A, Casado E, Cortés J. Ne�w approache�s in angioge�nic 
targe�ting for colore�ctal cance�r. World J Gastroenterol 200��� 13�� 
5�5��5���
                                                                          
S- Editor  Tian L    L- Editor  We�bste�r JR   E- Editor  Tian L
2�0 June� 10, 2011|Volume� 2|Issue� �|WJCO|www.wjgne�t.com
